Bellicum Pharmaceuticals, Inc., based in Houston, TX, is a leading biopharmaceutical company that specializes in the development of high-performance cellular immunotherapies to combat a wide range of cancers. Their innovative platform technology, including the GoCAR technology, aims to overcome clinical barriers and unleash the full potential of cellular immunotherapies, with a particular focus on chimeric antigen receptor (CAR) cell therapy. Bellicum is dedicated to impacting more patients than ever before by engineering powerful and persistent cellular immunotherapies. Bellicum Pharmaceuticals, Inc. is at the forefront of the future of cellular immuno-oncology (IO), offering investigational immunotherapies that feature their proprietary GoCAR technology. With a commitment to delivering durable patient responses, Bellicum has developed a robust pipeline of cellular immunotherapies that hold great promise in the fight against cancer. Through their cutting-edge research and development efforts, Bellicum is revolutionizing the field of cellular IO and striving to make a significant impact on the lives of cancer patients worldwide.
Generated from the website